Industry

Industry in One Page

Managed health care is a financing-and-control system. Employers, governments, and individuals fund care; insurers and PBMs negotiate provider and drug economics; profits come from keeping medical and pharmacy cost trend below the premium, fee, or savings guarantee sold to the client. In employer health care, the employer is often the real risk-taker while the insurer supplies administration, networks, data, and stop-loss. Good cycles show up in stable enrollment, premium yield above cost trend, favorable MCR, and retained PBM clients; bad cycles show up first in utilization, provider and drug unit costs, reserve development, and regulatory scrutiny.

Industry Scale Snapshot. The arena is enormous, but the investable profit pools are narrow because most dollars pass through to providers, pharmacies, drugmakers, or members.

CMS reported U.S. national health expenditures of $5.3 trillion in 2024, equal to 18.0% of GDP, with private health insurance spending of $1.6 trillion. KFF's 2025 employer survey reported average annual employer-sponsored premiums of $9,325 for single coverage and $26,993 for family coverage, while 67% of covered workers were in self-funded plans.

Industry Map. Money moves from sponsors and taxpayers through insurers and PBMs to providers, pharmacies, and drugmakers; bargaining power depends on scale, local networks, and who bears claim risk.

How This Industry Makes Money

The form is simple; the risk transfer is not. Insurers earn premiums or administrative fees, PBMs earn claim and pharmacy-service economics, and both depend on scale, contracting, and cost control outrunning medical and drug inflation. In insured plans, the health plan bears claim risk for a fixed premium. In ASO arrangements, the employer funds claims and pays the plan to administer benefits, access networks, and manage care. PBMs design formularies, process drug claims, contract with pharmacies and manufacturers, and may operate mail-order or specialty pharmacies.

Profit-Pool Map. The highest accounting margin is not always the best economic pool; ASO and PBM services can be capital-light while fully insured benefits carry more claim and regulatory capital risk.

Cigna's FY2025 segment disclosures show the contrast. Evernorth Health Services generated $235.0 billion of adjusted revenue at a 3.1% pre-tax adjusted margin, while Cigna Healthcare generated $47.2 billion at an 8.8% pre-tax adjusted margin and an 84.4% medical care ratio. That is not a whole-industry margin claim; it is a public-company lens on why scale PBM revenue can look huge while the real economics sit in small basis-point differences.

Demand, Supply, and the Cycle

The cycle is driven less by GDP than by employment coverage, government eligibility, provider and drug inflation, and the lag between when health plans price premiums and when claims are incurred. Premiums are usually priced before the contract year, so a sudden change in utilization, unit cost, or drug mix can hit MCR before pricing catches up. PBM cycles are more client-renewal and mix-driven: volumes matter, but the claims composition between generic, branded, biosimilar, GLP-1, and specialty drugs can change revenue and profit in different directions.

Cycle Driver Scorecard. Watch where the shock appears first: medical claims for insurers, prescription mix for PBMs, and client retention for employer-service platforms.

The lag is the point. A health plan can know medical trend is rising and still be stuck with filed rates until renewal; a PBM can grow claims volume and still lose profit if renewals require more value sharing or transition investment. That is why professionals read MCR, pharmacy claim volume, pricing commentary, and reserve development before broad health-spending headlines.

Competitive Structure

Managed health care is both consolidated and local: national scale matters in PBMs and large-employer accounts, but local provider networks and regulated state markets still decide medical cost competitiveness. The PBM layer is especially concentrated: the FTC's 2024 interim report said the six largest PBMs managed nearly 95% of U.S. prescriptions, and the top three processed nearly 80% of about 6.6 billion prescriptions dispensed by U.S. pharmacies in 2023. Commercial health insurance is also concentrated locally; the AMA reported that 97% of metro-area markets were highly concentrated in 2024, up from 95% in 2014 under federal merger-guideline thresholds.

Peer Structure. The public peer set is made of different business mixes, so revenue scale alone does not tell you whether the risk is employer medical trend, Medicare Advantage, Medicaid rates, retail pharmacy, or PBM regulation.

The main competitive axes are not only price. Large employers care about service reliability, network breadth, stop-loss terms, specialty-drug management, data feeds, and performance guarantees. Governments care about bids, star ratings, network adequacy, compliance, and risk adjustment. PBM clients care about drug affordability, rebate pass-through, specialty pharmacy access, transparency, and operational execution.

Regulation, Technology, and Rules of the Game

Rules are not background noise in managed care; they define what can be priced, how much premium can become margin, which utilization tools are allowed, and how transparent the economics must become. Technology only changes industry economics when it lowers administrative cost, improves routing to lower-cost care, helps employers understand prices, or changes the evidence used in coverage and prior authorization.

Rules of the Game. Regulation sets the maximum extractable margin in insurance and is increasingly targeting the parts of PBM economics that used to be least visible.

For investors, regulation matters only when it changes claim costs, allowable pricing, rebate economics, administrative cost, or customer switching. PBM transparency and rebate-free models are the live issue because they can convert opaque economics into explicit fees and service value.

The Metrics Professionals Watch

Professionals watch operating metrics that connect pricing to claims, claims to reserves, and service promises to client retention. GAAP net margin is useful, but in this industry it is too far downstream to diagnose whether the problem is medical trend, drug mix, contract pricing, or regulatory pressure.

Metrics Scorecard. The most valuable metrics are leading diagnostics of claim trend, contract repricing, and PBM mix rather than generic profitability ratios.

For Cigna specifically, the first metric to anchor is Cigna Healthcare MCR: FY2025 was 84.4%, and the April 30, 2026 release gave a full-year 2026 outlook range of 83.7% to 84.7%. For Evernorth, the comparable anchor is not an MCR but adjusted revenue, pre-tax adjusted income, pharmacy claim volume, specialty mix, and client retention.

Where The Cigna Group Fits

The Cigna Group is best understood as a scale health-services and employer-benefits platform, not as a pure health insurer. After the March 19, 2025 sale of its Medicare Advantage, Medicare stand-alone Part D, Medicare supplement, and CareAllies businesses to HCSC, the company's mix is more concentrated in Evernorth pharmacy and specialty services, U.S. employer benefits, international health, and ASO relationships. Management also announced on the April 30, 2026 earnings call that it plans to exit the individual exchange business at the end of 2026, reinforcing the tilt away from less-scaled government and individual risk pools.

Company Positioning. Cigna sits at the intersection of PBM scale and employer health benefits, with less direct Medicare Advantage exposure than several managed-care peers.

The key interpretation is mix. Cigna's PBM and specialty platforms create enormous revenue throughput, but the earnings signal is in margin basis points, retention, and specialty mix. Cigna Healthcare has smaller revenue but clearer underwriting metrics, especially MCR and medical customer mix.

What to Watch First

The fastest read on Cigna's backdrop is medical trend, PBM contract economics, and regulatory pressure, not broad health-spending growth. Start with Cigna Healthcare MCR against the 83.7% to 84.7% 2026 outlook range; a sustained move above the range would point to pricing or utilization pressure. Then watch employer affordability and rebids: premium growth helps revenue only if large employers do not buy down benefits or push harder on fees.

For Evernorth, the test is pharmacy claim volume, specialty growth, and pre-tax adjusted income against the 2026 outlook of at least $6.9 billion; volume without margin is not enough. PBM rulemaking, FTC actions, state laws, and rebate-free adoption determine whether economics shift from spread and rebate pools into explicit service fees. Large-client concentration, provider and pharmacy network disruptions, and government-program policy remain on the dashboard because each can reshape pricing even after Cigna's portfolio exits.